Journals / Anatolian Current Medical Journal / 2026 / Volume: 8 Issue: 5

Analgesic use patterns and medication overuse headache in patients with migraine followed in a neurology outpatient clinic

Pages
—
Publication Date
2026-09-11
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

Routine assessment of analgesic use behaviors and patient education regarding appropriate analgesic use may facilitate the early identification and management of patients at risk for MOH.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Aims: This study aimed to evaluate analgesic use patterns, factors associated with medication overuse headache (MOH), and patients' awareness regarding analgesic overuse in patients with migraine.
📊
Key Findings & Data:Methods: This cross-sectional study included 116 patients with migraine followed in a tertiary neurology outpatient clinic.
💡
Conclusion & Impact:Routine assessment of analgesic use behaviors and patient education regarding appropriate analgesic use may facilitate the early identification and management of patients at risk for MOH.
🔬Design:Survey & Empirical Study
📍Scope:Comprehensive Sample
⚙️Variables:Migraine · medication overuse headache · analgesic use

Abstract

Aims: This study aimed to evaluate analgesic use patterns, factors associated with medication overuse headache (MOH), and patients' awareness regarding analgesic overuse in patients with migraine. Methods: This cross-sectional study included 116 patients with migraine followed in a tertiary neurology outpatient clinic. Demographic and clinical characteristics, analgesic use patterns, prophylactic treatment use, and MOH awareness were evaluated using a structured questionnaire. Headache-related disability was assessed using the Headache Impact Test-6 (HIT-6). MOH was diagnosed according to ICHD-3 criteria. Results: The prevalence of MOH was 33.6% among patients with migraine and was significantly higher in patients with chronic migraine (CM) compared with those with episodic migraine (EM) (94.7% vs. 21.6%, p<0.001). In multivariable logistic regression analysis, smoking (OR: 5.298, 95% CI: 2.127-13.899; p<0.001) and the number of emergency department visits (OR: 1.622, 95% CI: 1.287-2.150; p<0.001) were independently associated with the presence of MOH. Only 41.4% of patients reported being aware of MOH, whereas most patients (63.8%) reported making their own decisions regarding analgesic use. Conclusion: MOH is a common condition associated with substantial disease burden, particularly among patients with CM. Routine assessment of analgesic use behaviors and patient education regarding appropriate analgesic use may facilitate the early identification and management of patients at risk for MOH.

🔖

Cite This Article

Şener, D. K., Kandemir, F. N., Kamışlı, Ö. (2026). Analgesic use patterns and medication overuse headache in patients with migraine followed in a neurology outpatient clinic. Anatolian Current Medical Journal, Volume: 8 Issue: 5. https://doi.org/10.38053/acmj.1958196

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (23)

  1. Dong L, Dong W, Jin Y, Jiang Y, Li Z, Yu D. The global burden of migraine: a 30-year trend review and future projections by age, sex, country, and region. Pain Ther. 2025;14(1):297-315. doi:10.1007/s40122-024-00690-7
  2. Ertas M, Baykan B, Orhan EK, et al. One-year prevalence and the impact of migraine and tension-type headache in Turkey: a nationwide home-based study in adults. J Headache Pain. 2012;13(2):147-157. doi:10.1007/s10194-011-0414-5
  3. Steiner TJ, Stovner LJ, Jensen R, Uluduz D, Katsarava Z; Lifting The Burden: the Global Campaign against Headache. Migraine remains second among the world's causes of disability, and first among young women: findings from GBD2019. J Headache Pain. 2020;21(1):137. doi:10.1186/s10194-020-01208-0
  4. GBD 2016 Neurology Collaborators. Global, regional, and national burden of neurological disorders, 1990-2016: a systematic analysis for the Global Burden of Disease Study 2016. Lancet Neurol. 2019;18(5):459-480. doi:10.1016/S1474-4422(18)30499-X
  5. Headache Classification Committee of the International Headache Society (IHS). The international classification of headache disorders, 3rd edition. Cephalalgia. 2018;38(1):1-211. doi:10.1177/0333102417738202
  6. Ashina S, Terwindt GM, Steiner TJ, et al. Medication overuse headache. Nat Rev Dis Primers. 2023;9(1):5. doi:10.1038/s41572-022-00415-0
  7. Diener HC, Holle D, Dresler T, Gaul C. Chronic headache due to overuse of analgesics and anti-migraine agents. Dtsch Arztebl Int. 2018; 115(22):365-370. doi:10.3238/arztebl.2018.0365
  8. Rueda-Sánchez M, Díaz-Martínez LA. Prevalence and associated factors for episodic and chronic daily headache in the Colombian population. Cephalalgia. 2008;28(3):216-225. doi:10.1111/j.1468-2982.2007.01499.x
  9. Schwedt TJ. Chronic migraine. BMJ. 2014;348:g1416. doi:10.1136/bmj.g1416
  10. Dikmen PY, Bozdağ M, Güneş M, et al. Reliability and validity of Turkish version of Headache Impact Test (HIT-6) in patients with migraine. Noro Psikiyatr Ars. 2020;58(4):300-307. doi:10.29399/npa.24956
  11. Westergaard ML, Hansen EH, Glümer C, Jensen RH. Prescription pain medications and chronic headache in Denmark: implications for preventing medication overuse. Eur J Clin Pharmacol. 2015;71(7):851-860. doi:10.1007/s00228-015-1858-3
  12. Westergaard ML, Hansen EH, Glümer C, Olesen J, Jensen RH. Definitions of medication-overuse headache in population-based studies and their implications on prevalence estimates: a systematic review. Cephalalgia. 2014;34(6):409-425. doi:10.1177/0333102413512033
  13. Bendtsen L, Munksgaard S, Tassorelli C, et al. Disability, anxiety and depression associated with medication-overuse headache can be considerably reduced by detoxification and prophylactic treatment. Results from a multicentre, multinational study (COMOESTAS project). Cephalalgia. 2014;34(6):426-433. doi:10.1177/0333102413515338
  14. Diener HC, Holle D, Solbach K, Gaul C. Medication-overuse headache: risk factors, pathophysiology and management. Nat Rev Neurol. 2016; 12(10):575-583. doi:10.1038/nrneurol.2016.124
  15. Shand B, Goicochea MT, Valenzuela R, et al. Clinical and demographical characteristics of patients with medication overuse headache in Argentina and Chile: analysis of the Latin American section of COMOESTAS project. J Headache Pain. 2015;16:83. doi:10.1186/s10194-015-0561-1
  16. Zwart JA, Dyb G, Hagen K, Svebak S, Stovner LJ, Holmen J. Analgesic overuse among subjects with headache, neck, and low-back pain. Neurology. 2004;62(9):1540-1544. doi:10.1212/01.wnl.0000123262.96132.fc
  17. Becerra L, Bishop J, Barmettler G, et al. Triptans disrupt brain networks and promote stress-induced CSD-like responses in cortical and subcortical areas. J Neurophysiol. 2016;115(1):208-217. doi:10.1152/jn.00632.2015
  18. Shin HE, Park JW, Kim YI, Lee KS. Headache Impact Test-6 (HIT-6) scores for migraine patients: their relation to disability as measured from a headache diary. J Clin Neurol. 2008;4(4):158-163. doi:10.3988/jcn.2008.4.4.158
  19. Sarchielli P, Corbelli I, Messina P, et al. Psychopathological comorbidities in medication-overuse headache: a multicentre clinical study. Eur J Neurol. 2016;23(1):85-91. doi:10.1111/ene.12794
  20. Wang YF, Yu CC, Kuan AS, Chen SP, Wang SJ. Association between suicidal risks and medication-overuse headache in chronic migraine: a cross-sectional study. J Headache Pain. 2021;22(1):36. doi:10.1186/s10194-021-01248-0
  21. Hagen K, Linde M, Steiner TJ, Stovner LJ, Zwart JA. Risk factors for medication-overuse headache: an 11-year follow-up study. The Nord-Trøndelag Health Studies. Pain. 2012;153(1):56-61. doi:10.1016/j.pain.2011.08.018
  22. Carlsen LN, Munksgaard SB, Nielsen M, et al. Comparison of 3 treatment strategies for medication overuse headache: a randomized clinical trial. JAMA Neurol. 2020;77(9):1069-1078. doi:10.1001/jamaneurol.2020.1179
  23. Hagen K, Albretsen C, Vilming ST, et al. Management of medication overuse headache: 1-year randomized multicentre open-label trial. Cephalalgia. 2009;29(2):221-232. doi:10.1111/j.1468-2982.2008.01711.x